Form 4: Gilead Sciences Executive Deborah H. Telman Reports Stock Transactions

Sentiment:

SEC Form 4 Filing


EVP Deborah H. Telman reports stock transactions including the vesting of restricted stock units and stock options, as well as adjustments for employee stock purchase plan acquisitions.

Summary

  • On March 10, 2025, Deborah H. Telman, EVP, Corporate Affairs & GC of Gilead Sciences, Inc., reported transactions involving Gilead's common stock and derivative securities.
  • Telman acquired 3,343 shares of common stock through the vesting of restricted stock units.
  • She also disposed of 1,130 shares to cover tax obligations at a price of $117.21 per share.
  • Following these transactions, Telman directly owns 36,562 shares of Gilead common stock.
  • Additionally, Telman acquired 33,940 non-qualified stock options and 7,680 restricted stock units.
  • The reported transactions also reflect shares acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing reflecting standard executive compensation practices. There are no indications of unusual or concerning activity.

Positives

  • The acquisition of stock options and restricted stock units indicates continued alignment of executive incentives with company performance.

Negatives

  • The disposal of shares to cover tax obligations, while common, slightly reduces Telman's direct holdings.

Industry Context

Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, which is closely monitored by investors for signals about the company's prospects.

Comparison to Industry Standards

  • Executive compensation packages including stock options and restricted stock units are common across the pharmaceutical industry, aligning executive interests with shareholder value.
  • Companies like Amgen (AMGN) and Johnson & Johnson (JNJ) also utilize similar equity-based compensation strategies for their executives.
  • The vesting schedules described are typical, with quarterly vesting after an initial cliff vest.

Stakeholder Impact

  • The transactions have a minor impact on shareholders, providing transparency into executive compensation and alignment with company performance.
  • Employees participating in the Employee Stock Purchase Plan benefit from the opportunity to acquire company stock.

Key Dates

DateDescription
03/10/2025Date of earliest transaction: vesting of restricted stock units, disposal of shares for tax obligations, acquisition of stock options and restricted stock units.
03/12/2025Date of signature for the Form 4 filing.
03/10/2035Expiration date of the non-qualified stock options.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.